New combo aims to stop breast cancer return after surgery
NCT ID NCT02654119
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase II study tested a combination of two chemotherapy drugs (cyclophosphamide and paclitaxel) plus the targeted drug trastuzumab given after surgery to 20 patients with early-stage HER2-positive breast cancer. The goal was to see if this regimen is safe and can help prevent the cancer from coming back. Researchers tracked side effects like low white blood cell counts, nerve damage, and heart problems, as well as how long patients stayed cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide, paclitaxel, and trastuzumab
- What this could lead to
- If successful, this combination could help prevent HER2+ breast cancer from coming back after surgery.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply to everyone. Side effects like low white blood cell counts and nerve damage are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faith Regional Health Services Carson Cancer Center
Norfolk, Nebraska, 68701, United States
-
Nebraska Medicine-Village Pointe
Omaha, Nebraska, 68118, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Gene test could guide breast cancer treatment to boost survival
- Vaccine aims to block return of aggressive breast cancer
- New combo shows promise for aggressive breast cancer
- Could a skin gel help fight breast cancer? early trial tests endoxifen
- Shorter radiation course may spare breast cancer patients side effects